Shanghai Leader Peptide Biotechnology
Finnrick has tested 64 samples from Shanghai Leader Peptide Biotechnology across 5 products.
Take Action
Request Full Data Access to the Finnrick database of peptide tests.
Products
| Tests | ||||||||
|---|---|---|---|---|---|---|---|---|
| Product | Rating | Count | Avg | Min | Max | Oldest | Most Recent | |
| BPC-157 | 4 | 29 Dec 2025 | 2 Jun 2026 | |||||
| GHK-Cu | 10 | 11 Feb 2026 | 13 Jul 2026 | |||||
| Retatrutide | 25 | 29 Dec 2025 | 30 Jul 2026 | |||||
| Tesamorelin | 9 | 29 Jan 2026 | 4 Jun 2026 | |||||
| Tirzepatide | 12 | 11 Feb 2026 | 22 Jul 2026 | |||||
The Shanghai Leader Peptide Biotechnology samples tested by Finnrick were either acquired by Finnrick directly, or submitted by the public.
Customer Reviews
These indicators of customer satisfaction are based on reports submitted by the public through the Finnrick testing program, and are not verified.
Based on 38 overall satisfaction reports
People who submitted test requests to Finnrick gave Shanghai Leader Peptide Biotechnology an average satisfaction rating of 5.0 out of 5 across 38 reports associated with samples received and tested by Finnrick. Customers rated payment methods (4.3/5) comparatively lower.
Most recent Shanghai Leader Peptide Biotechnology tests
Samples are tested in commercial labs
tests
products
Scores
First
Last
| Quantity | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Product | Certificate | Test Score | Label | Tested | Difference | Purity | Endotoxins | Batch ID | Container | Tested At | Sent By |
| 30 Jul 2026 | Retatrutide | View | 10mg | 10.4mg | +4.0% | 99.60% | n/a | March 15 2026 | No label / Silver crimp / Yellow cap | Lab G | Public | |
| 22 Jul 2026 | Tirzepatide | View | 60mg | 55.6mg | -7.3% | 99.90% | n/a | H0308 | No label / Silver crimp / Green cap | Lab E | Public | |
| 20 Jul 2026 | Tirzepatide | View | 20mg | 17.6mg | -12.0% | 99.90% | not detected | TR20BT | No label / Silver crimp / Black cap | Lab E | Public | |
| 20 Jul 2026 | Retatrutide | View | 20mg | 18.7mg | -6.5% | 96.40% | not detected | RT20WT | No label / Silver crimp / White cap | Lab E | Public | |
| 20 Jul 2026 | Retatrutide | View | 10mg | 11mg | +10.0% | 99.80% | n/a | 3/17/2026 | No label / Silver crimp / Blue cap | Lab G | Public | |
| 13 Jul 2026 | GHK-Cu | View | 100mg | 116.8mg | +16.8% | 99.90% | n/a | H0304 | No label / Silver crimp / Gray cap | Lab E | Public | |
| 13 Jul 2026 | Tirzepatide | View | 20mg | 17.3mg | -13.5% | 99.90% | n/a | TR20-04-26 | White label / Blue crimp / White cap | Lab E | Public | |
About Shanghai Leader Peptide Biotechnology Test Results From Finnrick
Shanghai Leader Peptide Biotechnology is a peptide vendor with multiple products tracked in the independent testing dataset collected by Finnrick. This page compiles recent, batch-level test results across 5 products and 64 tests, including scores, test dates, batch IDs, and lab details. This enables you to compare quality over time, not just marketing claims.
Each tested sample receives a 0–10 score, with 10 being the best possible value. It is the total of three components: purity (0–4 points), quantity accuracy vs. the label or batch claim (0–4 points), and batch information quality (0–2 points).
When several test results are available for a product and vendor pair, you’ll also find a Finnrick Rating (A–E, where A is best and E is worst, X if an insufficient number of tests is available, or F in rare cases of documented and widespread fraud) and customer satisfaction reports with sub-scores that provide additional context. Use the table above to review purity, quantity accuracy, consistency between batches, and any notable outliers surfaced in Finnrick testing data.
Shanghai Leader Peptide Biotechnology Testing Activity & Score Summary
In the past 30 days, Finnrick has published no new test results for Shanghai Leader Peptide Biotechnology, and 10 in the past three months. The overall dataset includes 64 tested samples with an average score of 6.8/10 across all products.
Across 60 identity-tested samples, 93% were confirmed to contain the expected peptide (identity pass rate). Among those that passed, median purity was 99.8%. Approximately 98% of passing samples tested at or above 98% purity.
Here is a closer look at the most frequently tested products (top 3):
- Retatrutide (25 tests, 88% identity pass, median purity 99.8%) — Test scores are highly variable, ranging from 2.0 to 10.0 (average 7.4/10), suggesting significant batch-to-batch differences.
- Tirzepatide (12 tests, 92% identity pass, median purity 99.9%) — Test scores are highly variable, ranging from 0.0 to 10.0 (average 6.9/10), suggesting significant batch-to-batch differences.
- Tesamorelin (9 tests, 100% identity pass, median purity 99.8%) — Test scores are highly variable, ranging from 2.2 to 6.9 (average 5.3/10), suggesting significant batch-to-batch differences.